The FDA just approved the first-ever mRNA flu vaccine, a genuine public health breakthrough that is about 27% more effective than the shot you've been getting for years. The man whose boss spent the last year canceling nearly $500 million in mRNA vaccine research did not manage to stop it. The man's boss is now going to try to make sure you can't actually get it.
What Got Approved and Why It Matters
Moderna's mFLUSIVA received FDA approval on Wednesday for adults 50 and older, making it the first influenza vaccine built on mRNA technology to clear that bar in the United States. According to NBC News, the approval covers two groups: full approval for adults 50 to 64, and accelerated approval for adults 65 and older, with the condition that Moderna run an additional clinical trial for the older cohort.
The case for an mRNA flu vaccine has been sitting in plain sight for years. Traditional flu shots take roughly six months from strain selection to distribution. Moderna says its mRNA version cuts that to two to three months. That gap matters enormously because flu strains mutate constantly, and picking the wrong one six months out is exactly the kind of educated guessing the current system forces scientists to do.
"If you're choosing the strain half a year before, how good can we be at sharpshooting?" Dr. Ofer Levy, director of the Precision Vaccines Program at Boston Children's Hospital, told NBC News. Traditional flu shots have an effectiveness range of 22% to 56%, according to the Mayo Clinic. "We wish it were higher, quite frankly," Levy said. mFLUSIVA outperformed a standard flu shot by about 27% in a late-stage trial of more than 40,000 adults across 11 countries.
The Part Where the Government Tried to Kill It
Here is how a normal regulatory process works: a company submits a rigorous clinical trial, federal scientists review it, and if the data holds up, the drug gets approved. Here is how this one went.
Earlier this year, CBS News reports, the FDA sent Moderna a refusal-to-file letter, saying it would not even consider the application. FDA vaccine director Dr. Vinay Prasad faulted the trial design for comparing mFLUSIVA against a standard flu shot in adults 65 and older, rather than the high-dose flu vaccine the CDC recommends for that age group. Moderna's position, according to NBC News, is that the FDA had already signed off on that trial design before the company ran the thing. The FDA reversed course about a week later after discussions with Moderna led to what CBS News described as a "revised regulatory approach and an amended application."
In June, the FDA's independent vaccine advisory committee unanimously recommended approval. Wednesday's decision follows that recommendation. The science was never really the problem here.
RFK Jr.'s Fingerprints Are All Over This Mess
Robert F. Kennedy Jr. runs the Department of Health and Human Services, which oversees the FDA. He has called the COVID mRNA vaccines "the deadliest vaccine ever made." Last year, NBC News reports, HHS under Kennedy canceled nearly $500 million in funding for mRNA vaccine research, including, CBS News notes, 22 separate vaccine development projects.
None of that stopped this approval, which is a credit to the scientists and career staff who held the line. But it does paint a very clear picture of the environment these researchers have been operating in. The secretary of health for the United States of America spent a year actively trying to strangle a category of vaccine technology that just produced a better flu shot than anything currently on the market. That is not a subtext situation. That is the text.
Moderna, for its part, kept its statement anodyne and professional: "This approval also reflects the ongoing potential of our mRNA platform to help address important public health challenges through continued scientific innovation." Good for them for not saying what everyone is thinking.
Approved Doesn't Mean You Can Get It
Here is where the story gets grimmer. Moderna says mFLUSIVA will be available for the 2026-27 flu season, which is right now. But available and accessible are two very different words.
Vaccines in the U.S. are typically formally recommended by the CDC's Advisory Committee on Immunization Practices, known as ACIP, before they enter widespread use. ACIP's sign-off is what triggers insurance coverage, federal distribution programs like Vaccines for Children and Medicaid, and clear public guidance on who should get the shot. NBC News reports that a federal judge has blocked ACIP from convening. The committee literally cannot meet.
Dr. Levy told NBC News that mFLUSIVA could still be legally prescribed without ACIP's recommendation, but that most patients would not be able to get insurance coverage for it, since private insurers generally follow ACIP guidance. Federal programs that cover vaccines for children and lower-income adults would also be in limbo. "That is a serious concern," Levy said. So the U.S. has a better flu vaccine. Adults 50 and older are approved to receive it. And a significant portion of the people who need it most may not be able to afford or access it because the machinery designed to distribute vaccines has been deliberately broken.
The Dingo Take
A man who canceled half a billion dollars in mRNA research runs the agency that just approved an mRNA vaccine. A committee that cannot legally meet is the only thing standing between this approval and actual public access to the shot. A federal judge's order is doing more damage to flu season preparedness than any virus. This is the American healthcare system in 2026: the science works, the approval happened, and the government's own architecture of obstruction may still win.
The flu kills tens of thousands of Americans in a bad year. Hundreds of thousands end up hospitalized. The people most at risk are older adults, exactly the population this vaccine targets. Those people now technically have access to a meaningfully better flu shot, and many of them will likely be blocked from getting it by a combination of insurance bureaucracy, frozen federal guidance, and an HHS secretary who thinks mRNA is the enemy. That is not regulatory caution. That is ideological sabotage with extra steps.
Moderna ran a 40,000-person trial across 11 countries. Its independent advisory committee voted unanimously. The FDA, despite spending several months trying to find reasons not to, ultimately approved it. The science did everything it was supposed to do. What happens next depends entirely on whether an administration that has spent 18 months treating public health as a culture war target will allow the people who actually need this vaccine to get one. History suggests we should not hold our breath.
Comments